Description of Medical ServiceAxicabtagene ciloleucel is a CAR T-cell product produced using a patient’s own T-cells, making the product unique to each patient. A patient’s T-cells are collected via a process called leukapheresis. The T-cells are genetically modified in a lab to express an anti-CD19 chimeric antigen receptor (CAR) which targets the lymphoma B-cells. Following modification and subsequent proliferation, the T-cells are infused back into the patient where they target and kill the lymphoma B-cells.
Description of Medical ConditionLarge B-cell lymphoma (LBCL) is a collection of entities that are subtypes of non-Hodgkin’s lymphoma. LBCL accounts for roughly one third of all cases of non-Hodgkin’s lymphoma. Patients typically present with progressive lymphadenopathy, extranodal disease or both.
Reason for ApplicationHighly Specialised Therapy - National Health Reform Agreement
Medical Service TypeTherapeutic technology
Previous Application Number/sNot Applicable
Application FormApplication Form (PDF 1204 KB)
Application Form (Word 415 KB)
Consultation SurveyConsultation Survey (PDF 658 KB)
Consultation Survey (Word 27 KB)
Expedited – Bypassing PASC
MSAC consultation input closed Friday, 10 February 2023.
For further information please refer to PASC, ESC, MSAC Key Dates
For further information on the consultation process please refer to MSAC Consultation Process
Public Summary DocumentPublic Summary Document (PDF 1121 KB)
Public Summary Document (Word 609 KB)